<p>CSTONE PHARMA-B (02616.HK) announced that the final analysis results of the international multicenter Phase III study of nofazinlimab for the treatment of hepatocellular carcinoma showed a significant clinical benefit trend in overall survival when comparing nofazinlimab combined with lenvatinib to placebo combined with lenvatinib, although it did not reach statistical significance, it still demonstrated tangible patient benefits. In addition, the safety profile of nofazinlimab was good, consistent with previous study results and the safety characteristics of marketed anti-PD-(L) 1 antibodies, with no new safety signals observed</p>

02616

<p>CSTONE PHARMA announced the final analysis results of the Phase III study of nofazinlimab for the treatment of hepatocellular carcinoma, showing that the drug combined with lenvatinib demonstrated a significant clinical benefit trend in overall survival compared to placebo combined with lenvatinib, although it did not reach statistical significance. In addition, the safety profile of nofazinlimab was good and consistent with previous study results, with no new safety signals observed</p>

基石药业宣布 nofazinlimab III 期研究最终分析结果